Amedisys (AMED) PT Cut to $47 at Mizuho Following Results
- Wall Street lower as oil snaps four-day rally
- Equinix (EQIX) Announces $3.6B Acquisition of Data Center Portfolio from Verzion (VZ)
- Deal Progress Said to Slow as Johnson & Johnson (JNJ) Puts Actelion (ALIOY) Under Microscope - Source
- Trump Wants to Cancel New Air Force One Order with Boeing (BA)
- Roper Industries (ROP) to acquire Deltek in $2.8B Deal
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Mizuho Securities analyst Sheryl Skolnick reiterated a Neutral rating and lowered her price target on Amedisys (NASDAQ: AMED) to $47.00 following results.
Skolnick commented, "What the new team has done for AMED in a very short period of time seems close to a miracle given the company's starting point: Training 11k people & 50% of agencies on a new IT system at one time, dealing with a 1,000-year flood and only missing by $0.05? But, we want to see 4Q16 execution against our more de-risked (lower) estimates. Still, the stock seems modestly undervalued, but not by enough to rate a 'Buy.' New $47 PT still values 38% growth rather richly. Let's let them get there."
Shares of Amedisys closed at $43.78 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Stifel Downgrades PennTex Midstream Partners, LP (PTXP) to Hold
- UPDATE: Stifel Downgrades Arc Logistics Partners (ARCX) to Hold
- UPDATE: Stifel Upgrades Green Plains Partners LP (GPP) to Buy
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!